Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality rate. Because the signaling pathways activated by several tyrosine kinase receptors have been shown to be involved in lung fibrosis, it has been suggested that the inhibition of these receptors may slow the progression of idiopathic pulmonary fibrosis. METHODS: In a 12-month, phase 2 trial, we assessed the efficacy and safety of four different oral doses of the tyrosine kinase inhibitor BIBF 1120 as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Secondary end points included acute exacerbations, quality of life (measured with the St. George's Respiratory Questionnaire [SGRQ]), and total lung capacity. RESULTS: A total of 432 patients underwent randomization to receive one of four doses of BIBF 1120 (50 mg once a day, 50 mg twice a day, 100 mg twice a day, or 150 mg twice a day) or placebo. In the group receiving 150 mg of BIBF 1120 twice a day, FVC declined by 0.06 liters per year, as compared with 0.19 liters per year in the placebo group, a 68.4% reduction in the rate of loss with BIBF 1120 (P = 0.06 with the closed testing procedure for multiplicity correction; P = 0.01 with the hierarchical testing procedure). This dose also resulted in a lower incidence of acute exacerbations, as compared with placebo (2.4 vs. 15.7 per 100 patient-years, P = 0.02) and a small decrease in the SGRQ score (assessed on a scale of 0 to 100, with lower scores indicating better quality of life) as compared with an increase with placebo (-0.66 vs. 5.46, P = 0.007). Gastrointestinal symptoms (which led to more discontinuations in the group receiving 150 mg twice a day than in the placebo group) and increases in levels of liver aminotransferases were more frequent in the group receiving 150 mg of BIBF 1120 twice daily than in the placebo group. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, BIBF 1120 at a dose of 150 mg twice daily, as compared with placebo, was associated with a trend toward a reduction in the decline in lung function, with fewer acute exacerbations and preserved quality of life. (Funded by Boehringer Ingelheim; ClinicalTrials.gov number, NCT00514683 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Bayesian approach incorporated dynamic borrowing of historical placebo data from several external IPF trials, including the ASCEND, INPULSIS, and TOMORROW studies (Figures E2 and E3).2,3,13”
From Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial (2026) · cites this paper as [13]
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Self-citationClinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationBois, R. M. D., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201007-1179oc · Cited by 465
Self-citation
Cited by
Items 601–700 of 1,000
Recent advances in managing idiopathic pulmonary fibrosis
Scelfo, C., Caminati, A., & Harari, S. A. (2017) · F1000Research · doi:10.12688/f1000research.10720.1 · Cited by 15
Shukla, S. K., Kadry, H., Bhatt, J. A., Elbatanony, R. S., Ahsan, F., & Gupta, V. (2020) · Bioanalysis · doi:10.4155/bio-2019-0284 · Cited by 14
Dobashi, M., Tanaka, H., Taima, K., Itoga, M., Ishioka, Y., Shiratori, T., Okumura, F., Tabe, C., Tanaka, Y., Morimoto, T., et al. (2021) · SAGE Open Medicine · doi:10.1177/20503121211023357 · Cited by 14
Bosch‐Barrera, J., Verdura, S., Ruffinelli, J. C., Carcereny, E., Sais, È., Cuyàs, E., Palmero, R., López‐Bonet, E., Hernández, A., Oliveras, G., et al. (2021) · Cancers · doi:10.3390/cancers13164168 · Cited by 14
Progression of Idiopathic Pulmonary Fibrosis Is Associated with Silica/Silicate Inhalation
Koga, Y., Satoh, T., Kaira, K., Hachisu, Y., Ishii, Y., Yajima, T., Hisada, T., Yokoo, H., & Dobashi, K. (2021) · Environmental Science & Technology Letters · doi:10.1021/acs.estlett.1c00659 · Cited by 15
Microbiota and IPF: hidden and detected relationships.
Fabbrizzi, A., Nannini, G., Lavorini, F., Tomassetti, S., & Amedei, A. (2021) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v38i3.11365 · Cited by 17
Londner, C., Dandachi, G. A., Plantier, L., Juvin, K., Chevalier-Bidaud, B., Mahut, B., Israël‐Biet, D., & Delclaux, C. (2013) · Respiration · doi:10.1159/000351110 · Cited by 14
Senhaji, L., Senhaji, N., Abbassi, M., Karhate, M., Serraj, M., Biaze, M. E., Benjelloun, M. C., Ouldim, K., Bouguenouch, L., & Amara, B. (2026) · Biomedicines · doi:10.3390/biomedicines14010090 · Cited by 14
Recent Advances (2015–2020) in Drug Discovery for Attenuation of Pulmonary Fibrosis and COPD
Dorababu, A., & Maraswami, M. (2023) · Molecules · doi:10.3390/molecules28093674 · Cited by 15
Luppi, F., Manfredi, A., Faverio, P., Franco, G., Salvarani, C., Bendstrup, E. M., & Sebastiani, M. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103668 · Cited by 16
Combined therapy with pirfenidone and nintedanib counteracts fibrotic silicosis in mice
Bai, L., Wang, J., Wang, X., Wang, J., Zeng, W., Pang, J., Zhang, T., Li, S., Song, M., Shi, Y., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17390 · Cited by 15
Activity of nintedanib in germ cell tumors
Steinemann, G., Jacobsen, C., Gerwing, M., Hauschild, J., Amsberg, G. V., Höpfner, M., Nitzsche, B., & Honecker, F. U. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000305 · Cited by 13
Existing and emerging treatments for idiopathic pulmonary fibrosis
Kolilekas, L., Papiris, S. A., & Bouros, D. E. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1568244 · Cited by 15
Minimal clinically important difference in idiopathic pulmonary fibrosis
Kang, M., Marts, L. T., Kempker, J. A., & Veeraraghavan, S. (2021) · Breathe · doi:10.1183/20734735.0345-2020 · Cited by 17
Iwanami, Y., Ebihara, K., Nakao, K., Sato, N., Miyagi, M., Nakamura, Y., Sakamoto, S., Kishi, K., Homma, S. A., & Ebihara, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185336 · Cited by 15
Khan, M. A., Sherbini, N., Alyami, S., Al-Harbi, A., Alghamdi, M. A., Alrajhi, S., Rajendram, R., & Al-Jahdali, H. H. (2023) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_206_22 · Cited by 14
Çilli, A., Öcal, N., Üzer, F., Çoşkun, F., Sevinç, C., Ursavaş, A., Yildiz, P., Deniz, P. P., Demirci, N. Y., Ozbey, G., et al. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.04.007 · Cited by 13
Gümüştaş, S., Inan, N., Akansel, G., Başyïğït, I., & Cïftçi, E. (2013) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 27
Miyazaki, Y., Azuma, A., Inase, N., Taniguchi, H., Ogura, T., Inoue, E., Takeuchi, M., Yoshizawa, Y., Sugiyama, Y., & Kudoh, S. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.05.002 · Cited by 13
Bax-inhibiting peptide attenuates bleomycin-induced lung injury in mice
Suzuki, K., Yanagihara, T., Yokoyama, T., Maeyama, T., Ogata-Suetsugu, S., Arimura‐Omori, M., Mikumo, H., Hamada, N., Harada, E., Kuwano, K., et al. (2017) · Biology Open · doi:10.1242/bio.026005 · Cited by 14
Jones, I. C., Espíndola, M. S., Narayanan, R., Coelho, A. L., Habiel, D. M., Boehme, S. A., Ly, T. W., Bacon, K. B., & Hogaboam, C. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-56393-z · Cited by 14
Nintedanib-induced glomerular microangiopathy: a case report
Hasegawa, M., Uehara, A., Suzuki, T., Sekine, R., Yazawa, M., Ichikawa, D., Koike, J., & Shibagaki, Y. (2020) · CEN Case Reports · doi:10.1007/s13730-020-00474-w · Cited by 15
Assayag, D., Vittinghoff, E., Ryerson, C. J., Cocconcelli, E., Tonelli, R., Hu, X., Elicker, B. M., Golden, J. A., Jones, K. D., King, T. E., et al. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.06.012 · Cited by 14
NICE guidance on nintedanib for treating idiopathic pulmonary fibrosis
Laurenson, S. X., Sidhu, R., Goodall, M., & Adler, A. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)00022-9 · Cited by 13
Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard
Wells, A. U. (2015) · European Respiratory Journal · doi:10.1183/09031936.00043915 · Cited by 14
Nili, M., Epstein, A. J., Nunag, D., Olson, A. L., & Borah, B. J. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02496-3 · Cited by 13
Impact of reduction in antifibrotic treatment on mortality in idiopathic pulmonary fibrosis
Porse, S., Hoyer, N., & Shaker, S. B. (2022) · Respiratory Medicine · doi:10.1016/j.rmed.2022.107015 · Cited by 12
Yamada, T., Nakashima, T., Masuda, T., Sakamoto, S., Yamaguchi, K., Horimasu, Y., Miyamoto, S., Iwamoto, H., Fujitaka, K., Hamada, H., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6169 · Cited by 13
Yang, S., Wang, J., Sun, D., Wang, Y., Xue, C., & Ye, Q. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1246767 · Cited by 14
Watanabe, N., Sakamoto, K., Taniguchi, H., Kondoh, Y., Kimura, T., Kataoka, K., Ono, K., Fukuoka, J., Nishiyama, O., & Hasegawa, Y. (2014) · Respiration · doi:10.1159/000358098 · Cited by 12
Advances in the treatment of idiopathic pulmonary fibrosis
Sergew, A., & Brown, K. M. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1102886 · Cited by 12
Self-citationKuse, N., Abe, S., Hayashi, H., Kamio, K., Saito, Y., Usuki, J., Azuma, A., Kudoh, S., & Gemma, A. (2016) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 13
Choudhary, R., Kumar, A., Ali, O., & Pervez, A. (2022) · Cureus · doi:10.7759/cureus.29435 · Cited by 15
Targeting the myofibroblast to improve wound healing
Hinz, B. (2016) · Elsevier eBooks · doi:10.1016/b978-1-78242-455-0.00003-3 · Cited by 13
A Small Change in FVC But a Big Change for IPF: Defining the Minimal Clinically Important Difference
Behr, J. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201110-1794ed · Cited by 12
Idiopatic pulmonary fibrosis: A new paradigm
Avdeev, S. N. (2017) · Terapevticheskii arkhiv · doi:10.17116/terarkh2017891112-122 · Cited by 13
Management of Idiopathic Pulmonary Fibrosis
Cerri, S., Spagnolo, P., Luppi, F., & Richeldi, L. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.11.005 · Cited by 13
Self-citationHashemian, S. M. R., Farhadi, T., Varahram, M., & Velayati, A. A. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2153116 · Cited by 11
Decoding the role of fatty acids and their metabolites in lung fibrosis
Wygrecka, M., Hadžić, S., Potaczek, D. P., Alexopoulos, I., Agha, E. E., & Schaefer, L. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16520 · Cited by 14
Sofia, C., Comes, A., Sgalla, G., & Richeldi, L. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2281416 · Cited by 11
Self-citationImperatorin ameliorates pulmonary fibrosis via GDF15 expression
Tsai, C., Chen, Y.-C., Li, Y., Wu, C.-T., Chang, P.-C., & Yeh, W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1292137 · Cited by 11
Pr, G. (2014) · Lung India · doi:10.4103/0970-2113.125899 · Cited by 15
Treatment of interstitial lung diseases associated with connective tissue diseases
Kobayashi, A., & Okamoto, H. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.9 · Cited by 11
Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians
Houron, C., Danielou, M., Mir, O., Fromenty, B., Perlemuter, G., & Voican, C. S. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103127 · Cited by 14
Troy, L. K., Chapman, S. A., Lake, F., WILSHER, M. L., Honeysett, L., Macansh, S., & Corte, T. J. (2015) · Respirology · doi:10.1111/resp.12512 · Cited by 11
Anti-fibrotic nintedanib—a new opportunity for systemic sclerosis patients?
Duarte, A. C., Santos, M. J., & Cordeiro, A. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3867-3 · Cited by 11
Idiopathic Pulmonary Fibrosis Pathogenesis and Novel Approaches to Immunomodulation
Wells, A. U., & Kelleher, W. P. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201302-0336ed · Cited by 12
An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis
Ford, P., Kreuter, M., Brown, K. K., Wuyts, W. A., Wijsenbeek, M. S., Israël‐Biet, D., Hubbard, R., Nathan, S. D., Nunès, H., Penninckx, B., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00636-2023 · Cited by 10
Self-citationSuzuki, Y. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.12.009 · Cited by 13
Maher, T. M., Song, J. W., Kramer, M. R., LANCASTER, L. H., Corte, T. J., Yun, J. H., Kim, K., Cho, J., Sather, L., George, P. M., et al. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-003038 · Cited by 12
Bi, Y., Rekić, D., Paterniti, M. O., Chen, J., Marathe, A., Chowdhury, B. A., Karimi-Shah, B. A., & Wang, Y. (2020) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-020-09718-9 · Cited by 10
Mekhael, O., Naiel, S., Vierhout, M., Hayat, A. I., Revill, S. D., Abed, S., Inman, M. D., Kolb, M. R. J., & Ask, K. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1382-5_21 · Cited by 12
Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis
Li, Y., Jiang, C., Zhu, W., Lu, S., Yu, H., & Meng, L. (2024) · Science Progress · doi:10.1177/00368504241247402 · Cited by 11
Promising advances in treatments for the management of idiopathic pulmonary fibrosis
Sofia, C., Comes, A., Sgalla, G., & Richeldi, L. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2354460 · Cited by 11
Self-citationConsensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis
Cordeiro, C. R., Campos, P., Carvalho, L., Campainha, S., Clemente, S., Figueiredo, L., Jesus, J. M., Marqués, J., Souto-Moura, C., Basto, R. P., et al. (2016) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2016.01.003 · Cited by 18
Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis
Shimomura, I., Abe, M., Yu, L., Tsushima, K., Sakao, S., Tanabe, N., Ikusaka, M., & Tatsumi, K. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1384-18 · Cited by 10
Singh, S., Bairwa, M. L., Collins, B. F., Sharma, B. B., Joshi, J. M., Talwar, D., Singh, N., Pilania, K., Bhattacharya, P., Gupta, N., et al. (2020) · Lung India · doi:10.4103/lungindia.lungindia_414_20 · Cited by 10
Self-citationCardiovascular safety of the tyrosine kinase inhibitor nintedanib
Ameri, P., Tini, G., Spallarossa, P., Mercurio, V., Tocchetti, C. G., & Porto, I. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14793 · Cited by 12
Lacedonia, D., Correale, M., Tricarico, L., Scioscia, G., Stornelli, S. R., Simone, F., Casparrini, M., Brunetti, N. D., & Barbaro, M. P. F. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02883-w · Cited by 11
Cottin, V., Bonniaud, P., Cadranel, J. L., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, É., et al. (2022) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.01.014 · Cited by 14
Nakshbandi, G., Moor, C. C., Antoniou, K. M., Cottin, V., Hoffmann‐Vold, A., Koemans, E. A., Kreuter, M., Molyneaux, P. L., Wuyts, W. A., & Wijsenbeek, M. S. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02336-4 · Cited by 11
Pharmacological inhibition of MDM4 alleviates pulmonary fibrosis
Mei, Q., Yang, Z., Xiang, Z., Zuo, H., Zhou, Z., Dong, X., Zhang, L., Song, W., Wang, Y., Hu, Q., et al. (2023) · Theranostics · doi:10.7150/thno.81993 · Cited by 10
Han, C. Q., Wang, L., Dong, Z.-Q., Wang, P., Lv, Y., Wang, D., & Hu, L. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-08052-7 · Cited by 11
Sandbo, N. K. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_8 · Cited by 13
Idiopathic pulmonary fibrosis: A guide for nurse practitioners
Vega‐Olivo, M., & Criner, G. J. (2018) · The Nurse Practitioner · doi:10.1097/01.npr.0000531121.07294.36 · Cited by 11
The microRNA-429/DUSP4 axis regulates the sensitivity of colorectal cancer cells to nintedanib
Cheng, G., Li, Y., Liu, Z., & Song, X. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.11867 · Cited by 12
Pirfenidone should be prescribed for patients with idiopathic pulmonary fibrosis: Table 1
Jenkins, G. R. (2013) · Thorax · doi:10.1136/thoraxjnl-2011-201268 · Cited by 10
Hot off the breath: a big step forward for idiopathic pulmonary fibrosis
Ryerson, C. J., & Collard, H. R. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-205892 · Cited by 10
Huang, T., Kuo, C., Chen, C., Tseng, Y., Wu, C., & Lin, S. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01559-7 · Cited by 10
At the frontiers of lung fibrosis therapy
(2013) · Nature Biotechnology · doi:10.1038/nbt.2687 · Cited by 10
Wu, X., Li, W., Luo, Z., & Chen, Y. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02861-w · Cited by 9
Syed, M. K. H., Bruck, O., Kumar, A., & Surani, S. (2023) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v12.i3.153 · Cited by 9
The use of mechanical ventilation in interstitial lung disease
Nolan, T., Dwyer, I., & Geoghegan, P. (2025) · Breathe · doi:10.1183/20734735.0172-2024 · Cited by 9
Wang, T., Cui, Z., Ou, Y., Lou, S., Chen, H., Zhu, C., Zhou, L., & Zou, F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1530697 · Cited by 17
Luo, M., Al-waqeerah, A., & Gao, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1742761 · Cited by 10
Antifibrotics and lung transplantation: A Spanish multicentre case‐controlled study
Cuesta, V. M. M., Fernandez, D. I., Ibáñez, S. A., Anguera, G., Iribarnegaray, J. M., Hernández-Rubio, J. C., Mezquida, J. P. R., Pérez-González, V. L., Hernández, R. L., Gafas, A. D. P., et al. (2022) · Respirology · doi:10.1111/resp.14352 · Cited by 9
Nawa, H., Hamano, H., Niimura, T., Miyata, K., Yagi, K., Goda, M., Zamami, Y., & Ishizawa, K. (2022) · Clinical and Translational Science · doi:10.1111/cts.13419 · Cited by 11
Omori, M., Minegishi, Y., Uruga, H., Fukuizumi, A., Isobe, K., Izumi, S., Koyama, R., Bando, M., Sugiyama, H., Takahashi, K., et al. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.06.002 · Cited by 9
Maher, T. M., Brown, K. K., Cunningham, S., DeBoer, E. M., Deterding, R. R., Fiorino, E. K., Griese, M., Schwerk, N., Warburton, D., Young, L. R., et al. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.26882 · Cited by 11
Self-citationSun, X., Wang, H., Zhan, X., Yan, Y., Chen, K., An, Z., & Zhou, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1256649 · Cited by 9
Management of interstitial lung disease in elderly patients
Meyer, K. C. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3283541337 · Cited by 10
Toi, Y., Kimura, Y., Domeki, Y., Kawana, S., Aiba, T., Ono, H., Aso, M., Tsurumi, K., Suzuki, K., Shimizu, H., et al. (2019) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v36i1.7383 · Cited by 10
Galectin-3 levels are elevated following nintedanib treatment
Shochet, G. E., Pomerantz, A., Shitrit, D., Bardenstein-Wald, B., Ask, K., Surber, M. W., Rabinowicz, N., Levy, Y. M., Benchetrit, S., Edelstein, E., et al. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320968412 · Cited by 9
Cottin, V., Bergot, E., BOURDIN, A. A., Nunès, H., Prévôt, G., Wallaert, B., & Marchand-Adam, S. (2021) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2020.100811 · Cited by 9
Nagel, D. J., Rackow, A. R., Ku, W.-Y., Bell, T. J., Sime, P. J., & Kottmann, R. M. (2022) · Cells · doi:10.3390/cells11162540 · Cited by 9
Suzuki, H., Hirashima, T., Kobayashi, M., Okamoto, N., MATSUURA, Y., Tamiya, M., Morishita, N., Okafuji, K., Shiroyama, T., Morimura, O., et al. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.82 · Cited by 9
Update in Diffuse Parenchymal Lung Disease 2011
Luckhardt, T., Müller–Quernheim, J., & Thannickal, V. J. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0509up · Cited by 11
Harmsen, S., & Kok, R. J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800672778 · Cited by 9
Use of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPF
Murray, L. A., Grainge, C., Wark, P. A. B., & Knight, D. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.003 · Cited by 12
Lyu, W., Wang, H., Ji, T., Liu, L., Chen, H., Fan, L., Zhong, G., Wan, N., Chen, S., Chen, J., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70217 · Cited by 10
Kette, S., Reccardini, N., Salton, F., Confalonieri, P., Andrisano, A. G., Chianese, M. I., Nes, A. D., Maggisano, M., Galantino, A., Nicolosi, S., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18030411 · Cited by 8
Amin, R., Vaishali, K., Maiya, A. G., Mohapatra, A. K., Acharya, V. K., Dale, M., & Alison, J. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-01877-4 · Cited by 8
Adams, G. L., & Hayes, W. (2025) · Pharmaceutical Sciences and Drug Design · doi:10.51847/ie5dkk27c3 · Cited by 8
Hasan, S., Awasthi, P., Malik, S., & Dwivedi, M. (2022) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2022.2147661 · Cited by 9
Majewski, S., Białas, A. J., Barczyk, A., Batura‐Gabryel, H., Buchczyk, M., Doboszyńska, A., Górska, K., Grabowska-Szkudlarz, L., Jagielska-Len, H., Jarzemska, A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144635 · Cited by 9
Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
Liu, J., Wang, F., Hong, Y., & Luo, F. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29266 · Cited by 8
Evaluating new treatment options.
Nathan, S. D. (2017) · PubMed · Cited by 9
Clinical Trials in IPF: What Are the Best Endpoints?
Spagnolo, P., Cocconcelli, E., & Cottin, V. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_19 · Cited by 9
Futuro del tratamiento farmacológico en fibrosis pulmonar idiopática
Molina‐Molina, M. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2019.05.008 · Cited by 10
Singer, D., Bengtson, L. G. S., Conoscenti, C., Anderson, A. J., Brekke, L. N., Shetty, S. S., & de Andrade, J. A. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2054203 · Cited by 8
Metadata
- Authors
- Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., Brun, M., Gupta, A., Juhel, N., Klüglich, M., & du Bois, R. M.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Ruhrlandklinik (DE)
- Asan Medical Center (KR)
- Royal Brompton Hospital (GB)
- Michigan Medicine (US)
- Duke Medical Center (US)
- University of Washington (US)
- Boehringer Ingelheim (France) (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-09-22
- Volume
- 365
- Issue
- 12
- Pages
- 1079-1087
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152974152
- Cited by
- 1,157
- References
- 22
- Citations by year
- 2026: 32 · 2025: 50 · 2024: 79 · 2023: 74 · 2022: 83 · 2021: 86 · 2020: 73 · 2019: 72 · 2018: 91 · 2017: 102 · 2016: 88 · 2015: 100 · 2014: 71 · 2013: 80 · 2012: 61
- FWCI
- 60.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, nintedanib, tyrosine kinase inhibitors, forced vital capacity decline, lung fibrosis progression, acute exacerbation, quality of life, gastrointestinal adverse effects, liver aminotransferases, dose comparison, St George's Respiratory Questionnaire, total lung capacity, drug safety and efficacy
- MeSH terms
- Adult, Aged, Alanine Transaminase, Aspartate Aminotransferases, Enzyme Inhibitors, Female, Humans, Indoles, Liver, Male, Middle Aged, Protein-Tyrosine Kinases, Vital Capacity, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.